Peripheral blood stem cell (PBSC) transplantation has become an established treatment option for a range of malignant and inherited diseases. PBSCs are usually cryopreserved in the presence of dimethyl sulfoxide (DMSO) and stored in liquid nitrogen. However, cryopreservation and thawing of PBSCs may affect cell viability, resulting in delayed engraftment and other risks related to low stem cell numbers [1] . DMSO is commonly used at a concentration of 10% during freezing of PBSCs. However, DMSO itself is toxic and lowering doses of DMSO may have a favorable effect on hematopoietic recovery after transplantation [2, 3] . Generally, PBSCs are thawed and infused without removal of DMSO. This has been associated with a wide range of adverse effects (AEs), ranging from minor to severe lifethreatening events [4, 5] . Although not all toxic events can be contributed to DMSO, grafts containing lower concentrations of DMSO typically display a reduced incidence of AEs [5, 6] . To decrease AEs and improve graft quality after thawing, it has been suggested to remove DMSO prior to transplantation [4, 7] using different washing systems [8, 9] . Here, we aimed to remove DMSO from long-term cryopreserved PBSCs using an automated, fully closed system and assessed effects on CD34+ stem cells, viability, and colony-forming capacity.
PBSCs were collected from patients and healthy donors (n = 12), aged 46.8 ± 12.9 years, according to the standardized procedures. Ethical permission no. GO15/352-I8 was obtained from the internal Ethical Review Board of the Hacettepe University. PBSCs were collected using Fenwal Amicus (Fresenius Kabi, IL, USA) in a total volume of 60 mL, consisting of 30% cells and 70% plasma and Heparin (H3393, Sigma-Aldrich). Cells were frozen in 10% DMSO and stored for 3.9 ± 2.0 years in liquid nitrogen. Stem cell collection bags (OriGen Biomedical, Cryostore CS500CN, TX, USA) were rapidly thawed and placed on ice. To remove DMSO, the cell suspensions were washed with a fully automated, closed system (Biosafe, Sepax2, Switzerland) using 500 mL Voluven™ (Pfizer, USA), while maintaining the volume at 60 mL.
Directly after thawing of the PBSCs and after washing, cells were counted and cell viability was assessed using 0.4% Trypan Blue and Acridine Orange. Cells were stained with anti-CD34 (clone 561, BioLegend) and CD45-PE (clone HI30, BioLegend). To assess apoptosis, cells were stained with Annexin-V-FITC and propidium iodide (BioLegend). Events were acquired using a FACSARIA (BD Biosciences, San Jose, CA, USA) and analyzed using FACSDIVA v8.0.1 software. Colony-forming capacity was tested using MethoCult TM H4434 Classic (Stem Cell Technologies, Vancouver, Canada). Statistical analyses were done using Microsoft® Excel® for Mac 2011, version 14.7.3. For paired analysis of groups Student's t-test was used.
Total cell counts before freezing of PBSCs was 1.38 × 10 10 ± 0.32 × 10 10 cells (n = 12), after thawing 0.99 × 10 10 ± 0.32 × 10 10 cells, and after washing 0.78 × 10 10 ± 0.23 × 10 10 cells. Washing of PBSCs resulted in minimal cell loss, with recovery of 80.7% of total cells in comparison to pre-washing cell numbers (Fig. 1a) . Cell viability was significantly increased (p < 0.01) after washing with 61.0 ± 13.9% viable cells before and 75.2 ± 9.7% after washing (Fig. 1b) . Apoptosis was significantly decreased (p < 0.05) after washing of PBSCs (Fig. 1c) . Therefore, forming units before and after washing of PBSC grafts (n = 12). CFU-GEMM colony-forming unit-granulocyte/erythroid/monocyte/macrophage, CFU-GM colony-forming unit-granulocyte/monocyte, BFU-E burst-forming unit-erythroblast. *p < 0.01 removal of DMSO and dead cells using automated washing resulted in minimal cell loss and increased cellular viability. The absolute number of CD34+ cells directly after thawing was 162.7 × 10 6 ± 81.8 × 10 6 and after washing 162.5 × 10 6 ± 87.2 × 10 6 , showing that washing resulted in depletion of non-viable CD34-negative cells and maximal recovery of viable CD34+ cells. The frequency of CD34 high cells was relatively increased (Figs. 2a,b) , whereas colony numbers (both BFU-E and CFU-GM) per 10 4 plated cells (p < 0.01) and per 10 3 CD34+ cells (p < 0.01) were relatively low after washing (Fig. 2c) . This is consistent with the fact that CD34 high cells have a higher long-term repopulation potential, are less differentiated, and therefore form fewer colonies in culture.
Here, the Sepax-2 system was used to remove DMSO and increase cell viability of the PBSC grafts. Washed cells showed increased viability in comparison to unprocessed PBSCs and contained increased levels of CD34 high cells. Manual washing with a simple saline/citrate solution can be used to deplete DMSO without significant loss of CD34+ cells, but with sustained engraftment potential, the downsides of manual washing include cell clumping, cell activation, and contamination, in addition to being timeconsuming and labor-intensive [7] . For automated washing, the Sepax S-100 (Biosafe) [8, 10] , Sepax-2 (Biosafe) [9] , Cytomate TM (Baxter Oncology) [11] , and Cobe 2991 Cell Processor (Terumo Medical Corporation) [12] have all shown to allow rapid processing and good recovery of viable CD34+ cells. Importantly, transplantation of washed cells resulted in similar engraftment characteristics, although with considerably less and lower-grade AEs [8, 10] . The Sepax-2 system was previously shown to eliminate >95% of the DMSO in the PBSC products and support a post-wash recovery of 80% [9] . Using this system, we found that post-wash cell viability was significantly enhanced, and virtually all CD34 cells present in the grafts were recovered.
In conclusion, washing of long-term frozen PBSC grafts using a fully automated, closed system results in high recovery of viable CD34+ cells. However, the effect on AEs after infusion and hematopoietic recovery, long-term repopulation potential of washed PBSCs, and the cost effectiveness of the procedure remain to be explored in a clinical setting.
